Zur Eyal
Compounding Pharmacist, Israel.
Int J Pharm Compd. 2019 Jan-Feb;23(1):23-31.
Primary focal hyperhidrosis is idiopathic, localized, uncontrollable, excessive, and unpredictable sweating beyond what is necessary to regulate body temperature. Primary hyperhidrosis is thought to affect approximately 2% to 3% of the population, and its effect on a patient's quality of life is very significant. Primary focal hyperhidrosis can be managed using various therapeutic options, including drugs (topical and systemic), nonsurgical interventions (e.g., iontophoresis, botulinum toxin injections), and surgery. This article, which is presented in 2 parts, is a comprehensive review of the topical, evidence-based treatments of primary focal hyperhidrosis, and it covers the following active pharmaceutical ingredients: aluminum salts, methenamine, glycopyrronium salts, oxybutynin chloride; the latter 2 ingredients will be discussed in part 2 of this article. This article discusses the evidence-based data that exists from clinical trials that support the use of topical medications to treat the pathology from efficacy and from a safety point of view. This review also discusses compounding considerations for professionally and safely compounding various topical preparations. In addition, a range of relevant formulas are attached to the article and can be used by compounding pharmacists.
原发性局灶性多汗症是特发性的、局限性的、无法控制的、过度的且不可预测的出汗,超出了调节体温所需的范围。原发性多汗症被认为影响约2%至3%的人口,其对患者生活质量的影响非常显著。原发性局灶性多汗症可通过多种治疗方法进行管理,包括药物(局部和全身用药)、非手术干预(如离子电渗疗法、肉毒杆菌毒素注射)和手术。本文分为两部分,是对原发性局灶性多汗症局部应用、基于证据的治疗方法的全面综述,涵盖以下活性药物成分:铝盐、乌洛托品、格隆溴铵盐、氯化奥昔布宁;后两种成分将在本文第二部分讨论。本文讨论了来自临床试验的循证数据,这些数据从疗效和安全性角度支持使用局部用药治疗该病。本综述还讨论了专业且安全地配制各种局部制剂的配方考量。此外,文章还附上了一系列相关配方,可供配制药剂师使用。